Evidence map›Paper›PMID 12368673›Full record

Trial reportAnnals of surgery2002

Beta-blockade and growth hormone after burn.

David W Hart, Steven E Wolf, David L Chinkes, Sofia O Lal, Peter I Ramzy, David N Herndon

Open access · greenAbstract readClinical TrialRandomized Controlled Trial
In one paragraph

Trial report in Annals of surgery, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Recombinant human growth hormone for treating burns and donor sites.The Cochrane database of systematic reviews · 2014
    Pooled it
  4. Trial
  5. Nutrition in Pediatric Burns.Seminars in plastic surgery · 2024
    Review
  6. Review
  7. Rehabilitative Exercise Training for Burn Injury.Sports medicine (Auckland, N.Z.) · 2021
    Review
  8. Review
  9. Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned.Burns : journal of the International Society for Burn Injuries · 2020
    Review
  10. Observational
  11. The Role of Mitochondrial Stress in Muscle Wasting Following Severe Burn Trauma.Journal of burn care & research : official publication of the American Burn Association · 2018
    Review
  12. Article
  13. Article
  14. Anabolic and anticatabolic agents in critical care.Current opinion in critical care · 2016
    Review
  15. The impact of severe burns on skeletal muscle mitochondrial function.Burns : journal of the International Society for Burn Injuries · 2013
    Review
  16. Whole body and skeletal muscle protein turnover in recovery from burns.International journal of burns and trauma · 2013
    Article
  17. Article
  18. What, how, and how much should patients with burns be fed?The Surgical clinics of North America · 2011
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

David W HartDepartment of Surgery, The University of Texas Medical Branch, Shriners Hospitals for Children, Galveston, Texas 77550, USA.
Steven E Wolf
David L Chinkes
Sofia O Lal
Peter I Ramzy
David N Herndon
Shriners Hospitals for Children - Erie · USShriners Hospitals for Children - Galveston · US

Funding

Project 9: The role of androgen/corticosteroid in fat, muscle and glucose metabolism of burn victimsP50GM060338 · NIGMS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SZABO, CSABA · 2000 to 2017
$24.2M
MODULATION OF THE POSTBURN HYPERMETABOLIC RESPONSER01GM056687 · NIGMS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI HERNDON, DAVID N. · 1998 to 2017
$9.0M
POSTDOCTORAL TRAINING IN TRAUMA &BURNST32GM008256 · NIGMS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI Celeste Campbell Finnerty, Oscar E. Suman-Vejas · 1990 to 2026
$4.0M
NIGMS NIH HHS 1P50GM60338-01NIGMS NIH HHS 2T32GM0825611NIGMS NIH HHS GM56687NIGMS NIH HHS P50 GM060338NIGMS NIH HHS R01 GM056687
6 · The paper itself

Abstract

objectiveTo determine whether propranolol and growth hormone (GH) have additive effects to combat burn-induced catabolism. SUMMARY BACKGROUND DATA: Both GH and propranolol have been attributed anabolic properties after severe trauma and burn. It is conceivable that the two in combination would have additive effects.

methodsFifty-six children with more than 40% TBSA burns were randomized to one of four anabolic regimens: untreated control, GH treatment, propranolol treatment, or combination GH plus propranolol therapy. Clinical treatment was identical for all groups. Resting energy expenditure was determined by indirect calorimetry and skeletal muscle protein kinetics were measured using stable amino acid isotope infusions before and after each anabolic regimen.

resultsThere were no differences in age, sex, or burn size between groups. Tachycardia and energy expenditure were decreased during propranolol treatment ( <.05). The net balance of muscle protein synthesis and breakdown was improved during propranolol and GH plus propranolol treatment ( <.05). There was no significant benefit of GH alone. No additive effect of combination therapy was seen.

conclusionsPropranolol is a strongly anabolic drug during the early, hypercatabolic period after burn. No synergistic effect between propranolol and GH was identified.

Indexed as

Adrenergic beta-AntagonistsBurnsChildDrug Therapy, CombinationEnergy MetabolismFemaleGrowth HormoneHumansMaleMetabolic DiseasesMuscle, SkeletalPropranololTrauma Severity IndicesAdrenergic beta-AntagonistsGrowth HormonePropranolol

Identifiers

PMID12368673
PMCPMC1422599
OpenAlexW2089914620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.